• admin@condrug.com
  • Mon - Sat: 8.00 am - 7.00 pm

We develop solutions for your clinical data needs

Linkedin-in Link
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Whatsapp

+1 (877) 703-6664

Free to Use
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Blog

Small Molecule Drugs

What Are PROTACs? How Protein Degraders Are Transforming Cancer Therapy

Learn how PROTACs (Proteolysis-Targeting Chimeras) work, why they can target “undruggable” cancer proteins, and how small molecule degraders like ARV-110 and ARV-471 are changing oncology treatment.

New Drugs

Zavegepant for Migraine: How This Intranasal CGRP Antagonist Is Changing Treatment

Learn what zavegepant is, how its intranasal CGRP receptor blockade works, and why it’s emerging as a fast, needle‑free option for acute migraine relief and prevention.

Pharmacovigilance

AI-Driven Pharmacovigilance: How Machine Learning Is Transforming Drug Safety

Discover how AI-driven pharmacovigilance is transforming drug safety from slow, retrospective reporting to real-time, data-driven surveillance. Learn how machine learning, NLP, and real-world data enable faster signal detection, smarter risk stratification, and proactive monitoring of adverse drug reactions.

Protein-Peptide Drugs

Why Tirzepatide Is a Breakthrough Peptide for Type 2 Diabetes and Obesity Treatment

Discover how tirzepatide, a dual GIP/GLP‑1 receptor agonist, is redefining peptide medicine with powerful glycemic control, significant weight loss, and once‑weekly dosing through advanced peptide engineering and clinical trial success.

Small Molecule Drugs

Oral Small Molecule GLP‑1 Agonists: Next‑Gen Pills for Type 2 Diabetes and Obesity

Discover how oral small molecule GLP‑1 receptor agonists are transforming treatment for type 2 diabetes and obesity by replacing injectable peptides like semaglutide with convenient, stable pills that improve access, adherence, and metabolic outcomes.

Pharmacovigilance
Abstract illustration of artificial intelligence analyzing medical and pharmacovigilance data for real‑time drug safety monitoring

How AI Is Transforming Pharmacovigilance into Real‑Time Drug Safety Intelligence

Discover how AI is reshaping pharmacovigilance from passive spontaneous reporting to real‑time drug safety intelligence. Learn about NLP, machine learning, and multi‑source surveillance that help regulators, pharma companies, and healthcare providers detect and manage emerging safety risks faster.

Small Molecule Drugs
Abstract illustration of AI algorithms designing small molecule drugs for precision, patient‑specific treatment

AI‑Designed Small Molecules: The Missing Link in Precision Medicine

Discover how AI‑designed small molecule drugs are transforming precision medicine. Learn how machine learning and generative models enable ultra‑selective, patient‑informed compounds optimized for specific mutations, biomarkers, and disease subgroups.

Protein-Peptide Drugs

Why Tirzepatide Is Revolutionizing Obesity Treatment | Dual GIP/GLP‑1 Peptide Explained

Discover how tirzepatide, a dual GIP and GLP‑1 receptor agonist, is transforming obesity and type 2 diabetes care with surgery‑rivaling weight loss, powerful glycemic control, and better metabolic health compared with traditional weight‑loss drugs.

Pharmacovigilance

AI in Pharmacovigilance: Transforming Drug Safety with Real‑Time Intelligence

Discover how AI is reshaping pharmacovigilance from manual case processing to a real‑time, 360° drug safety intelligence ecosystem. Learn how NLP, machine learning, and real‑world data improve signal detection, risk identification, and patient protection across the product life cycle.

New Drugs

Atogepant for Migraine Prevention: How It Works, Benefits & Clinical Trial Data

Learn what atogepant is, how this next-generation oral CGRP receptor antagonist works for migraine prevention, and key clinical trial results on efficacy, onset of action, and safety.

  • 1
  • 2
  • 3
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
Categories
  • New Drugs (53)
  • Pharmacovigilance (73)
  • Protein-Peptide Drugs (41)
  • Small Molecule Drugs (45)
Tags
adverse drug reactions adverse event detection AI in drug safety AI in Healthcare AI in Pharmacovigilance artificial intelligence deucravacitinib drug discovery Drug Safety GIP GIP GLP-1 dual agonist GLP-1 GLP-1 agonist healthcare AI healthcare data incretin therapy Life Sciences Machine Learning machine learning in healthcare machine learning in pharma] metabolic disease metabolic health migraine treatment NLP obesity treatment peptide therapeutics pharmacovigilance pharmacovigilance automation PROTACs real-world data] real-world evidence signal detection small molecule design small molecule drugs SURPASS trials targeted protein degradation tirzepatide TYK2 inhibitor type 2 diabetes type 2 diabetes treatment weight loss weight loss drugs weight loss medication [AI drug discovery [AI pharmacovigilance
Recent Posts
  • Gefapixant for Chronic Cough: How This P2X3 Antagonist Is Changing Treatment
    17/12/2025
  • What Is Retatrutide? Triple Agonist Weight Loss Drug Explained (GLP‑1, GIP, Glucagon)
    17/12/2025
  • Ensifentrine for COPD: Dual PDE3/4 Inhibitor Mechanism, Benefits & Clinical Data
    17/12/2025
  • Home
  • Workspace
  • Contacts

Copyright © 2026 ConDrug All Rights Reserved.

Linkedin-in Handshake